Hepatocellular Carcinoma Pipeline Report H1 2016 - Therapeutics Review of 129 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Hepatocellular Carcinoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Hepatocellular Carcinoma - Overview
  5. Pipeline Products for Hepatocellular Carcinoma - Comparative Analysis
  6. Hepatocellular Carcinoma - Therapeutics under Development by Companies
  7. Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes
  8. Hepatocellular Carcinoma Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Hepatocellular Carcinoma - Products under Development by Companies
  13. Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes
  14. Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
  • 4SC AG
  • AB Science SA
  • Acceleron Pharma, Inc.
  • ACROVIS Pharma AG
  • Adaptimmune Therapeutics Plc
  • Advenchen Laboratories, LLC
  • Alfact Innovation
  • Amgen Inc.
  • AndroScience Corporation
  • Arbutus Biopharma Corporation
  • ArQule, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Beijing Kawin Technology Share-Holding Co., Ltd.
  • Bio-Cancer Treatment International Limited
  • Bioneer Corporation
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • CASI Pharmaceuticals Inc.
  • CCRP Therapeutics GmbH
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Celsion Corporation
  • China Medical System Holdings Limited
  • Chroma Therapeutics Limited
  • CytRx Corporation
  • Daiichi Sankyo Company, Limited
  • Delcath Systems, Inc.
  • Dicerna Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/pjszrm/hepatocellular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs